BRIGHT MINDS BIOSCIENCES ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF BMB-101 IN PATIENTS WITH ABSENCE SEIZURES AND DEVELOPMENTAL AND ENCEPHALOPATHIC EPILEPSIES (DEE)

Reuters · 6d ago

Please log in to view news